WO2014011489A3 - Monoclonal antibodies for use in diagnosis and therapy of cancers and automimmune disease - Google Patents

Monoclonal antibodies for use in diagnosis and therapy of cancers and automimmune disease Download PDF

Info

Publication number
WO2014011489A3
WO2014011489A3 PCT/US2013/049368 US2013049368W WO2014011489A3 WO 2014011489 A3 WO2014011489 A3 WO 2014011489A3 US 2013049368 W US2013049368 W US 2013049368W WO 2014011489 A3 WO2014011489 A3 WO 2014011489A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
cancers
therapy
monoclonal antibodies
automimmune disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/049368
Other languages
French (fr)
Other versions
WO2014011489A2 (en
WO2014011489A8 (en
Inventor
Jeffrey Molldrem
Anna Sergeeva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
The University of Texas at Austin
Original Assignee
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UAA201501025A priority Critical patent/UA114108C2/en
Priority to AU2013288982A priority patent/AU2013288982B2/en
Priority to EA201590187A priority patent/EA034033B1/en
Priority to EP16152641.3A priority patent/EP3088421B1/en
Priority to CA2883056A priority patent/CA2883056C/en
Priority to HK15108802.4A priority patent/HK1208168B/en
Priority to JP2015521668A priority patent/JP6336696B2/en
Application filed by The University of Texas System, The University of Texas at Austin filed Critical The University of Texas System
Priority to PL16152641T priority patent/PL3088421T3/en
Priority to IN263DEN2015 priority patent/IN2015DN00263A/en
Priority to EP13816335.7A priority patent/EP2872174A2/en
Priority to KR1020157003610A priority patent/KR102049222B1/en
Priority to US14/413,833 priority patent/US9926380B2/en
Priority to CN201380042522.1A priority patent/CN104540522B/en
Priority to MX2015000450A priority patent/MX360984B/en
Publication of WO2014011489A2 publication Critical patent/WO2014011489A2/en
Publication of WO2014011489A3 publication Critical patent/WO2014011489A3/en
Anticipated expiration legal-status Critical
Priority to IL236664A priority patent/IL236664B/en
Priority to PH12015500074A priority patent/PH12015500074B1/en
Priority to ZA2015/00247A priority patent/ZA201500247B/en
Publication of WO2014011489A8 publication Critical patent/WO2014011489A8/en
Priority to US15/895,782 priority patent/US11192958B2/en
Priority to CY20191100490T priority patent/CY1121743T1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The specification describes the sequences for antibodies that recognize the HLA-A2- restricted peptide PR-1 in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided.
PCT/US2013/049368 2012-07-10 2013-07-03 Monoclonal antibodies for use in diagnosis and therapy of cancers and automimmune disease Ceased WO2014011489A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
UAA201501025A UA114108C2 (en) 2012-07-10 2013-03-07 Monoclonal antibody for use in the diagnosis and therapy of malignant tumors and autoimmune disease
KR1020157003610A KR102049222B1 (en) 2012-07-10 2013-07-03 Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
EP16152641.3A EP3088421B1 (en) 2012-07-10 2013-07-03 Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
CA2883056A CA2883056C (en) 2012-07-10 2013-07-03 Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
HK15108802.4A HK1208168B (en) 2012-07-10 2013-07-03 Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
JP2015521668A JP6336696B2 (en) 2012-07-10 2013-07-03 Monoclonal antibodies for use in diagnosis and treatment of cancer and autoimmune diseases
EA201590187A EA034033B1 (en) 2012-07-10 2013-07-03 Humanized antibodies for therapy of cancers
PL16152641T PL3088421T3 (en) 2012-07-10 2013-07-03 Monoclonal antibodies
IN263DEN2015 IN2015DN00263A (en) 2012-07-10 2013-07-03
EP13816335.7A EP2872174A2 (en) 2012-07-10 2013-07-03 Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
US14/413,833 US9926380B2 (en) 2012-07-10 2013-07-03 Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
AU2013288982A AU2013288982B2 (en) 2012-07-10 2013-07-03 Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
CN201380042522.1A CN104540522B (en) 2012-07-10 2013-07-03 For diagnose and treat cancer and the monoclonal antibody of autoimmunity disease
MX2015000450A MX360984B (en) 2012-07-10 2013-07-03 MONOCLONAL ANTIBODIES FOR USE IN THE DIAGNOSIS AND THERAPY OF CANCER AND AUTOIMMUNE DISEASES.
IL236664A IL236664B (en) 2012-07-10 2015-01-11 Monoclonal antibodies for use in the diagnosis and treatment of cancer and autoimmune diseases
PH12015500074A PH12015500074B1 (en) 2012-07-10 2015-01-12 Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
ZA2015/00247A ZA201500247B (en) 2012-07-10 2015-01-14 Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
US15/895,782 US11192958B2 (en) 2012-07-10 2018-02-13 Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
CY20191100490T CY1121743T1 (en) 2012-07-10 2019-05-07 MONOCLONAL ANTIBODIES FOR USE IN THE DIAGNOSIS AND TREATMENT OF CANCER AND AUTOIMMUNE DISEASE

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261669967P 2012-07-10 2012-07-10
US61/669,967 2012-07-10
US201261702916P 2012-09-19 2012-09-19
US61/702,916 2012-09-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/413,833 A-371-Of-International US9926380B2 (en) 2012-07-10 2013-07-03 Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
US15/895,782 Division US11192958B2 (en) 2012-07-10 2018-02-13 Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease

Publications (3)

Publication Number Publication Date
WO2014011489A2 WO2014011489A2 (en) 2014-01-16
WO2014011489A3 true WO2014011489A3 (en) 2014-03-13
WO2014011489A8 WO2014011489A8 (en) 2015-02-19

Family

ID=49916655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/049368 Ceased WO2014011489A2 (en) 2012-07-10 2013-07-03 Monoclonal antibodies for use in diagnosis and therapy of cancers and automimmune disease

Country Status (25)

Country Link
US (2) US9926380B2 (en)
EP (2) EP2872174A2 (en)
JP (1) JP6336696B2 (en)
KR (1) KR102049222B1 (en)
CN (1) CN104540522B (en)
AU (1) AU2013288982B2 (en)
CA (1) CA2883056C (en)
CY (1) CY1121743T1 (en)
DK (1) DK3088421T3 (en)
EA (1) EA034033B1 (en)
ES (1) ES2720291T3 (en)
HR (1) HRP20190939T1 (en)
HU (1) HUE043443T2 (en)
IL (1) IL236664B (en)
IN (1) IN2015DN00263A (en)
LT (1) LT3088421T (en)
MX (1) MX360984B (en)
PH (1) PH12015500074B1 (en)
PL (1) PL3088421T3 (en)
PT (1) PT3088421T (en)
RS (1) RS58755B1 (en)
SI (1) SI3088421T1 (en)
UA (1) UA114108C2 (en)
WO (1) WO2014011489A2 (en)
ZA (1) ZA201500247B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
RS62471B1 (en) * 2014-04-16 2021-11-30 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
KR102908806B1 (en) 2015-10-22 2026-01-07 주노 테라퓨틱스 게엠베하 Method for culturing cells and kits and devices therefor
MA45489A (en) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh CELL CULTURE PROCESSES, ASSOCIATED KITS AND APPARATUS
RU2761555C2 (en) 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Methods, sets, means and devices for transduction
CR20180229A (en) 2015-10-29 2018-08-24 Novartis Ag ANTIBODY CONJUGATES UNDERSTANDING A TOLL TYPE RECEIVER AGONIST
BR112019000071A2 (en) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc adjuvant antibody conjugates
AU2018260380B2 (en) 2017-04-27 2025-02-13 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
US12290564B2 (en) 2017-05-18 2025-05-06 Renovorx, Inc. Methods and apparatuses for treating tumors
KR20200021074A (en) 2017-06-14 2020-02-27 아디셋 바이오, 인크. Antibodies capable of binding HLA-A2 / TYRD in a HLA restricted manner and uses thereof
CN108611322B (en) * 2018-05-09 2020-02-11 邹畅 Breast cancer circulating tumor cell line CTC-3, culture medium, and establishment method and application of CTC-3
BR112021002390A2 (en) 2018-08-09 2021-05-11 Juno Therapeutics Inc processes to generate modified cells and their compositions
WO2020089343A1 (en) 2018-10-31 2020-05-07 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US20230192824A1 (en) * 2020-04-02 2023-06-22 United States Of America As Represented By The Secretary Of The Navy Antigen Binding Proteins to Class 5 ETEC Adhesins
GB202008860D0 (en) * 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
WO2023010004A1 (en) * 2021-07-26 2023-02-02 Cardone Michael H Methods and compositions related to mcl-1 and bim heterodimer antibodies
JP7842485B2 (en) * 2022-11-11 2026-04-08 レノボアールエックス，インコーポレイテッド Method and apparatus for delivering drugs through nutrient vessels
WO2025049921A1 (en) * 2023-08-30 2025-03-06 University Of Louisville Research Foundation, Inc. Methods for single molecule resolution of near full-length immunoglobulin heavy and light chain repertoires

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060167230A1 (en) * 2003-01-20 2006-07-27 Takaki Koga Anti-pci neutralizing antibody
WO2009073163A1 (en) * 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
US20100003254A1 (en) * 2005-04-08 2010-01-07 Chugai Seiyaku Kabushiki Kaisha Antibody Substituting for Function of Blood Coagulation Factor VIII
US20110293620A1 (en) * 2008-12-05 2011-12-01 Molldrem Jeffrey J Monoclonal Antibodies For Use In Diagnosis and Therapy of Cancers and Autoimmune Disease

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4843092A (en) 1986-04-25 1989-06-27 Hitoshi Shichi Immunosuppressive agent
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5141648A (en) 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
FR2658197B1 (en) 1990-02-14 1992-05-22 Inst Nat Sante Rech Med RESTRICTED MONOCLONAL ANTIBODIES RECOGNIZING A PEPTIDE ASSOCIATED WITH A MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGEN - APPLICATIONS TO DIAGNOSIS AND TREATMENT.
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5846225A (en) 1997-02-19 1998-12-08 Cornell Research Foundation, Inc. Gene transfer therapy delivery device and method
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1124568B1 (en) 1998-10-21 2007-08-22 Altor BioScience Corporation Polyspecific binding molecules and uses thereof
WO2004018619A2 (en) 2001-06-05 2004-03-04 Altor Bioscience Corporation P53 binding t cell receptor molecules and uses thereof
ATE478681T1 (en) 2001-07-02 2010-09-15 Aimsco Ltd USE OF POLYCLONAL ANTI-HIV GOAT SERA AS A THERAPEUTIC AGENT
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US8158385B2 (en) 2002-10-11 2012-04-17 Chugai Seiyaku Kabushiki Kaisha Cell death-inducing agent
FR2858235B1 (en) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement USE OF ANTIBODIES OPTIMIZED IN ADCC TO TREAT LOW PATIENT PATIENTS
KR20060130606A (en) 2003-12-12 2006-12-19 추가이 세이야쿠 가부시키가이샤 Cell death inducers
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090233318A1 (en) 2004-12-28 2009-09-17 Weidanz Jon A Methods of assaying vaccine potency
US20090042285A1 (en) 2004-05-27 2009-02-12 Weidanz Jon A Antibodies at T cell receptor mimics, methods of production and uses thereof
US20060034850A1 (en) 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20060045881A1 (en) 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines
US20060045884A1 (en) 2004-08-26 2006-03-02 Board Of Regents Vaccines for autoimmune and infectious disease
EP1927367A4 (en) 2005-05-18 2009-08-12 Univ Tokushima NOVEL PHARMACEUTICAL AGENT BASED ON AN ANTI-HLA ANTIBODY
CA2662798A1 (en) 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
WO2008007755A1 (en) 2006-07-13 2008-01-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
CL2008000719A1 (en) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku THERAPEUTIC AGENT FOR CANCER RESISTANT TO CHEMOTHERAPEUTIC AGENTS THAT UNDERSTAND AN ANTIBODY THAT RECOGNIZES IT CLASS I AS ACTIVE INGREDIENT; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH ANTIBODY; AND METHOD TO TREAT CANCER RESISTANT TO
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060167230A1 (en) * 2003-01-20 2006-07-27 Takaki Koga Anti-pci neutralizing antibody
US20100003254A1 (en) * 2005-04-08 2010-01-07 Chugai Seiyaku Kabushiki Kaisha Antibody Substituting for Function of Blood Coagulation Factor VIII
WO2009073163A1 (en) * 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
US20110293620A1 (en) * 2008-12-05 2011-12-01 Molldrem Jeffrey J Monoclonal Antibodies For Use In Diagnosis and Therapy of Cancers and Autoimmune Disease

Also Published As

Publication number Publication date
IL236664B (en) 2020-01-30
MX360984B (en) 2018-11-22
ES2720291T3 (en) 2019-07-19
MX2015000450A (en) 2015-07-14
PH12015500074A1 (en) 2015-03-02
WO2014011489A2 (en) 2014-01-16
CN104540522A (en) 2015-04-22
HRP20190939T1 (en) 2019-07-26
EA201590187A1 (en) 2015-06-30
PH12015500074B1 (en) 2015-03-02
PL3088421T3 (en) 2019-08-30
AU2013288982A2 (en) 2016-01-14
EP3088421A1 (en) 2016-11-02
ZA201500247B (en) 2023-04-26
LT3088421T (en) 2019-04-10
US20150191546A1 (en) 2015-07-09
AU2013288982B2 (en) 2018-04-26
DK3088421T3 (en) 2019-05-13
JP2015530359A (en) 2015-10-15
EP2872174A2 (en) 2015-05-20
IL236664A0 (en) 2015-02-26
JP6336696B2 (en) 2018-06-06
WO2014011489A8 (en) 2015-02-19
CN104540522B (en) 2018-05-01
AU2013288982A1 (en) 2015-01-29
UA114108C2 (en) 2017-04-25
HUE043443T2 (en) 2019-08-28
KR20150039774A (en) 2015-04-13
RS58755B1 (en) 2019-06-28
EA034033B1 (en) 2019-12-20
US20180371106A1 (en) 2018-12-27
IN2015DN00263A (en) 2015-06-12
SI3088421T1 (en) 2019-04-30
CA2883056A1 (en) 2014-01-16
CA2883056C (en) 2020-11-10
EP3088421B1 (en) 2019-02-27
US9926380B2 (en) 2018-03-27
US11192958B2 (en) 2021-12-07
KR102049222B1 (en) 2019-11-29
CY1121743T1 (en) 2020-07-31
PT3088421T (en) 2019-05-10
HK1208168A1 (en) 2016-02-26

Similar Documents

Publication Publication Date Title
WO2014011489A8 (en) Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
WO2011106300A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2012097313A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
WO2012170513A3 (en) He4 based therapy for malignant disease
IL233832B (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2015035250A3 (en) Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome
IL223070A0 (en) Apoptosis- inducing agents for the treatment of cancer and immune and autoimmune diseases
IL231702A0 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
IL214255B (en) Use of antibodies for the preparation of drugs for the treatment of cancer associated with tumor antigen and methods for diagnosing cancer associated with tumor antigen
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
WO2014052707A3 (en) Identification of tumor-protective epitopes for the treatment of cancers
IL227009B (en) Selection of drugs for the treatment of malignant cancer using an array based on antibodies
CR20120429A (en) METHODS FOR THE TREATMENT AGAINST SCAMOCELLULAR CARCINOMA OF HEAD AND NECK
PH12014502582B1 (en) Anti-TG2 Antibodies and Methods for Using the Same
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
WO2010065962A3 (en) Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
DK2665746T3 (en) Antibodies against the s100p protein for the treatment and diagnosis of cancer
Xu et al. Novel targeted therapy for advanced gastric cancer
HK1182922A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin d1
NZ626513A (en) Anti-cd98 antibodies and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13816335

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2883056

Country of ref document: CA

Ref document number: 2015521668

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14413833

Country of ref document: US

Ref document number: MX/A/2015/000450

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 236664

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12015500074

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: IDP00201500317

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 2013288982

Country of ref document: AU

Date of ref document: 20130703

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201590187

Country of ref document: EA

Ref document number: 2013816335

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20157003610

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015000370

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015000370

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150108